Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTINGUISH
2023-504686-23-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in anti-NMDA receptor encephalitis comparing Inebilizumab (Uplizna) arm with Placebo arm (2 arms). Primary endpoints: Change in mRS at 16 weeks and Inebilizumab safety (TEAEs and TES AEs). Planned start Oct 2023; status: authorised.
02
Drugs
inebilizumab
03
Conditions
anti-NMDA receptor encephalitis
Beyond the preview
Go deeper on 2023-504686-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504686-23-00.